Our mission is to improve the detection and treatment of cardiovascular disease through the development of diagnostic markers, predictors and novel therapies for cardiometabolic disorders.
We aim to discover new mechanisms in cardiometabolic disease that we can target with novel therapeutic agents. We also aim to detect early markers of disease to guide timely intervention. Our research revolves around two major themes: (i) uncovering mechanisms and identifying novel therapeutic targets in Heart Failure preserved Ejection Fraction (HFpEF); and (ii) diet-microbiome-metabolism interactions in cardiovascular disease.
Cardiometabolic diseases, which lead to heart attacks and stroke, have exploded in prevalence due to a 600 per cent increase in overweight and obesity rates over the last 40 years. Our work to enable earlier detection of cardiometabolic disorders, and thus enable earlier intervention, could have a transformative impact on the health of hundreds of millions of people around Australia and the world who are at risk of diabetes and cardiovascular disease.
In our first theme, we have developed comprehensive resources with which to make novel insights: our own diabetic cardiomyopathy clinic; cardiac MRI; metabolomics and genomics platforms; in vivo murine models; an ex vivo perfusion Langendorff model; iPSC-cardiomyocytes, including several lines carrying loss-or gain-of-function variants in metabolic pathways relevant for cardiovascular disease; and stable-isotope flux analysis.
In our second theme, we use matched diets, microbiome analysis, faecal and plasma metabolomics, and careful cardiovascular phenotyping, and have already identified several novel pathways.